ReviewBlood advances2020
Gilteritinib: potent targeting of FLT3 mutations in AML.
Mark Levis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
82 papers cite itlatest 60 shown
this papertrialcites it
ReviewBlood advances2020
Mark Levis et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.